Tuberculosis (TB) is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis. While multidrug treatment regimens are the standard of care, the lengthy treatment schedule and the emergence of drug-resistant TB highlight the need for new therapeutic options to address these challenges. Inosine-5′-monophosphate dehydrogenase (GuaB) is vital for bacterial survival and propagation; therefore, GuaB inhibitors are considered potential compounds to add to first-line TB treatment.
Researchers from Kevirx Inc. and collaborators have described the use of KVX-053, a PTP4A3 inhibitor aimed to be used for the prevention of COVID-19-associated cute lung injury (ALI).
With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine to protect against the chikungunya virus infection, Vimkunya is the first of its kind available in the U.S. for those age 12 and older.
A second pentavalent vaccine for preventing meningococcal disease has been approved by the U.S. FDA. GSL plc’s Penmenvy will now go up against Pfizer Inc.’s Penbraya, which had a two-year head start in the market.
Researchers from Shanxi Medical University, Nanjing Agricultural University and China Pharmaceutical University, have detailed the discovery and preclinical characterization of antibiotic candidates against multidrug-resistant gram-positive pathogens.
Amid an overall positive earnings report of $3.2 billion in 2024 revenues, Moderna Inc. disclosed that the U.S. FDA placed its norovirus vaccine on a phase III clinical hold due to a single adverse event of Guillain-Barré syndrome (GBS).
The boronic acid transition state inhibitors S-02030 and MB-076 were strategically designed to be active against cephalosporinases and carbapenemases, especially KPC (Klebsiella pneumoniae carbapenemase).
The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.
Two simultaneous but independent studies published in Science identified, by introducing mutants into its genome, the essential and nonessential genes of Plasmodium knowlesi, one of the malaria parasites related to the dreaded Plasmodium vivax. Their results could help in the development and prioritization of antimalarial strategies.
RSS
